Robert D. Troutman

TL;DR: The replication-defective adenovirus is a promising vaccine vector for development of an HIV-1 vaccine and elicited by a replication-incompetent Ad5 vector, used either alone or as a booster inoculation after priming with a DNA vector.

TL;DR: Results are suggestive of an immunization strategy for humans that is centered on use of the adenovirus vector and in which existing adenavirus immunity may be overcome by combined immunization with adjuvanted DNA and adenvirus vector boosting.

TL;DR: This development illustrates how the natural, in vivo mechanisms facilitating cell entry and virus replication can be utilized to achieve an optimal, in vitro assembly state of yeast-expressed HPV VLPs.

TL;DR: The DNA vaccine-elicited immune responses were weaker than those elicited by the Ad5 vaccine and highly variable; formulation with chemical adjuvants led to moderate increases in the levels of Gag-specific T cells.

TL;DR: Investigation of plasmid DNA vaccine formulations containing a nonionic triblock copolymer adjuvant and a cationic surfactant indicates that the addition of BAK to DNA/CRL1005 formulations leads to the formation of approximately 300 nm CRL 1005-BAK-DNA particles that enhance the cellular immune response in rhesus monkeys.